4.5 Article

Discovery of a novel acetylcholinesterase inhibitor by structure-based virtual screening techniques

期刊

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 22, 期 9, 页码 3181-3187

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2012.03.046

关键词

Acetylcholinesterase inhibitors; Virtual screening; Structure-based pharmacophore; Molecular dynamics; Drug-like property

资金

  1. DAAD
  2. National Science Foundation of China (NSFC) [30973608]

向作者/读者索取更多资源

Acetylcholinesterase (AChE) is considered to be one of the most important targets for the treatment of Alzheimer's disease (AD). Previously our group has reported a series of tacrine-based hybrids as potent AChE inhibitors (AChEI). To discover more novel scaffolds, molecular docking and dynamics stimulation were applied to acquire the binding models of AChE with the most prominent compounds from our work. A structure-based pharmacophore model plus shape constraints was generated from the binding models and it was then employed to virtually screen commercial databases, giving a focused hit list of candidates. Subsequently, we scored the hit compounds by their molecular binding energies, which were calculated by MM/PBSA method. Fifteen compounds were selected and purchased for testing their anti-AChE effects, while seven of them showed inhibitory effects with IC50 values ranging from 1.5 to 9.8 mu M. The drug-like properties of these compounds, including LogD, AlogP, molecular volume and Lipinski rule of five, were also calculated. Compounds 12 and 16 (IC50 = 2.5 and 1.5 mu M, respectively) exhibited potent activity and acceptable drug-like properties, thus might serve as leads for further modification. The data suggest that the presented model might be a valid approach for identification and development of new AChEIs. (C) 2012 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors

Xianglin Chu, Siyu He, Yang Liu, Yijun Liu, Feng Feng, Qinglong Guo, Li Zhao, Haopeng Sun

Summary: This article provides an overview of the physiological and pathological functions of human aldo-keto reductase family 1C1 (AKR1C1) and its relationship with diseases. It also summarizes the development of AKR1C1 inhibitors and the interaction between inhibitors and AKR1C1. Furthermore, it discusses the design ideals of selective AKR1C1 inhibitors and the prospects of AKR1C1 in disease treatment.

CHEMICO-BIOLOGICAL INTERACTIONS (2022)

Article Chemistry, Multidisciplinary

A Practical and High-Affinity Fluorescent Probe for Butyrylcholinesterase: A Good Strategy for Binding Affinity Characterization

Lei Wang, Chenxi Du, Hui Liu, Weimin Qiu, Xin Lu, Yanyu Hu, Yueqing Li, Tianyu Sun, Yao Chen, Haopeng Sun

Summary: In this study, small-molecule fluorescence probes for BChE were designed and shown to have potential in detecting the affinity of non-fluorescent compounds to BChE. This provides a solid foundation for the development of small-molecule BChE inhibitors and better understanding the molecular biological mechanism of BChE.

CHINESE JOURNAL OF CHEMISTRY (2022)

Review Biochemistry & Molecular Biology

Medicinal Prospects of Targeting Tyrosinase: A Feature Review

Yuanyuan Wang, Baichen Xiong, Shuaishuai Xing, Ying Chen, Qinghong Liao, Jun Mo, Yao Chen, Qi Li, Haopeng Sun

Summary: Tyrosinase is a bifunctional enzyme involved in melanogenesis. It is targeted for various applications such as skin whitening, anticancer treatment, antibacterial properties, and fruit and vegetable preservation. Medicinal chemists have developed diverse tyrosinase inhibitors with novel scaffolds and synergistic effects to regulate multiple targets. This review covers natural and synthetic tyrosinase inhibitors with potential applications in various fields.

CURRENT MEDICINAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement

Xuemei Wei, Guoqi Yu, Hualiang Shen, Yanjuan Luo, Tianbo Shang, Runpu Shen, Meiyang Xi, Haopeng Sun

Summary: Phosphodiesterase 4 (PDE4), highly expressed in mammalian brain, selectively hydrolyzes cAMP, a key regulator of brain functions such as learning and memory. Inhibiting PDE4 can improve cognitive deficits, but its clinical development is hindered by adverse effects. Research on PDE4 subtypes and the development of subtype-specific inhibitors show promise for improved therapeutic benefits and safety.

BIOORGANIC CHEMISTRY (2023)

Article Chemistry, Medicinal

Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer

Yang Liu, Yuting Chen, Jiheng Jiang, Xianglin Chu, Qinglong Guo, Li Zhao, Feng Feng, Wenyuan Liu, Xiaolong Zhang, Siyu He, Peng Yang, Pengfei Fang, Haopeng Sun

Summary: AKR1C3 is overexpressed in hormone-related cancers and is correlated with tumor development and aggressiveness. A new class of AKR1C3 inhibitors with potent inhibitory activity and selectivity for closely related isoforms has been developed. Co-administration of these inhibitors with doxorubicin can significantly reverse drug resistance in breast cancer cells. These AKR1C3 inhibitors may serve as effective adjuvants to overcome drug resistance in breast cancer treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease

Yuanyuan Wang, Baichen Xiong, Hongzhi Lin, Qi Li, Hongyu Yang, Yuting Qiao, Qihang Li, Ziwei Xu, Weiping Lyu, Wei Qu, Wenyuan Liu, Yao Chen, Feng Feng, Haopeng Sun

Summary: Designing and synthesizing multifunctional anti-AD hybrids, we found that the optimal hybrid 15a exhibited excellent AChE inhibitory activity and significant Nrf2 inductivity. It showed neuroprotective, antioxidant, and anti-inflammatory effects, improved cognition, and reduced proinflammatory factors levels. These findings highlight the potential of 15a as a promising compound for further research in AD treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Editorial Material Chemistry, Multidisciplinary

Editorial: Pharmaceutical insights into the triazoles: Recent advances

Xianqing Deng, Haopeng Sun, Bahaa G. M. Youssif

FRONTIERS IN CHEMISTRY (2023)

Review Chemistry, Medicinal

Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases

Hualiang Shen, Xinde Xu, Yalong Bai, Xiaoping Wang, Yibin Wu, Jia Zhong, Qiyi Wu, Yanjuan Luo, Tianbo Shang, Runpu Shen, Meiyang Xi, Haopeng Sun

Summary: The Kynurenine pathway (KP) is the primary pathway of L-tryptophan metabolism in mammals, and it produces neuroactive metabolites such as kynurenic acid (KA) and quinolinic acid (QA). Imbalance in KP has been associated with aging and neurodegenerative diseases (NDs), leading to the interest in targeting KP enzymes and metabolite-associated receptors, particularly kynurenine monooxygenase (KMO). Although several agents have shown significant improvement in animal models, only one aryl hydrocarbon receptor (AHR) agonist 30 (laquinimod) has entered clinical trials for treating Huntington's disease (HD). This review provides an overview of neuroactive KP metabolites, discusses KP dysregulation in aging and NDs, and summarizes the development of KP regulators in preclinical and clinical studies, offering insights into the potential of targeting KP for NDs treatment in the future.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease

Xu Tang, Shuaishuai Xing, Mingkang Ma, Ziwei Xu, Qianwen Guan, Yuting Chen, Feng Feng, Wenyuan Liu, Tingkai Chen, Yao Chen, Haopeng Sun

Summary: Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2), which is the most common genetic risk factor for PD. This publication provides a comprehensive overview of the structure, function, and mutations of LRRK2, as well as recent advances and challenges in developing LRRK2 inhibitors. The binding mechanisms, structure-activity relationships, and pharmacokinetic features of inhibitors are emphasized to guide the rational design of LRRK2 inhibitors.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Design and Synthesis of Sulfonium Derivatives: A Novel Class of α-Glucosidase Inhibitors with Potent In Vivo Antihyperglycemic Activities

Lu Lu, Jingyi Chen, Wenxiang Tao, Zhimei Wang, Dan Liu, Jiahui Zhou, Xiaoxing Wu, Haopeng Sun, Wei Li, Genzoh Tanabe, Osamu Muraoka, Bo Zhao, Liang Wu, Weijia Xie

Summary: We attempted double-spot structural modification on a side-chain moiety of sulfonium-type alpha-glucosidase inhibitors isolated from Salacia genus. We designed and synthesized a series of sulfonium salts with benzylidene acetal linkage at the C3 ' and C5 ' positions. In vitro enzyme inhibition evaluation showed that compounds with a strong electron-withdrawing group attached at the ortho position on the phenyl ring have stronger inhibitory activities. Notably, the most potent inhibitor 21b showed excellent hypoglycemic effects in mice, comparable to acarbose. Molecular docking of 21b revealed the importance of the newly introduced benzylidene acetal moiety in anchoring the molecule in the enzyme's concave pocket. The identification of 21b as a lead compound may enable structure modification and diversification of sulfonium-type alpha-glucosidase inhibitors.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC

Haojie Dong, Xiuquan Ye, Yasheng Zhu, Hao Shen, Hongtao Shen, Weijiao Chen, Minghui Ji, Mingming Zheng, Keren Wang, Zeyu Cai, Haopeng Sun, Yibei Xiao, Peng Yang

Summary: In this study, a series of Osimertinib derivatives were designed as fourth-generation inhibitors targeting Osimertinib-resistant NSCLC. The top candidate D51 showed potent inhibition against EGFR mutants, selectivity against wild-type forms, and favorable in vivo druggability.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Review Chemistry, Medicinal

Regulation of beta-amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

Weimin Qiu, Hui Liu, Yijun Liu, Xin Lu, Lei Wang, Yanyu Hu, Feng Feng, Qi Li, Haopeng Sun

Summary: Alzheimer's disease (AD) is a difficult to treat progressive neurodegenerative disease characterized by the accumulation of amyloid beta (A beta) plaques in the brain. A beta interacts with various receptors on the plasma membrane and mediates signaling pathways that contribute to the development of AD. Despite ongoing research, there are currently no effective medications for AD. This review discusses the importance of A beta in the pathogenesis of AD, recent progress in targeting A beta-related receptors and compounds, and the challenges and opportunities in developing effective therapies for AD.

MEDICINAL RESEARCH REVIEWS (2023)

Article Biochemistry & Molecular Biology

Discovery of thiazole salt AChE inhibitors and development of thiamine disulfide prodrugs targeting the central nervous system

Chang Liu, Manxing Zou, Jianguo Zuo, Huanfang Xie, Weiping Lyu, Jian Xu, Feng Feng, Haopeng Sun, Wenyuan Liu, Xueyang Jiang

Summary: The FDA has approved donepezil, a selective AChE inhibitor, as a first-line drug for mild to moderate AD, but patients taking donepezil often experience peripheral side effects. This study introduces a series of novel thiazole salt AChE inhibitors with nanomolar inhibitory effect on human AChE. Thiamine disulfide prodrugs based on these inhibitors are developed and shown to be converted into thiazole salt AChE inhibitors in the brain, with high brain exposure and stronger inhibitory effects compared to intestinal AChE in vivo. This study provides a possible basis for centrally targeted thiazole salt inhibitors in the treatment of neurodegenerative diseases.

BIOORGANIC CHEMISTRY (2023)

Article Chemistry, Medicinal

Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment

Siyu He, Xianglin Chu, Yujia Wu, Jiheng Jiang, Pengfei Fang, Yuting Chen, Yang Liu, Zhixia Qiu, Yibei Xiao, Zhiyu Li, Di Pan, Qian Zhang, Huanfang Xie, Shuaishuai Xing, Feng Feng, Wenyuan Liu, Qinglong Guo, Li Zhao, Peng Yang, Haopeng Sun

Summary: Aldo-keto reductase 1C3 (AKR1C3) has been found to be associated with tumor development and chemotherapy resistance. Inhibition of AKR1C3 activity can restore the chemosensitivity in ANT-resistant cancers. Biaryl-containing AKR1C3 inhibitors, particularly S07-1066, selectively block AKR1C3-mediated reduction and significantly enhance the cytotoxicity of doxorubicin (DOX) in MCF-7 cells overexpressing AKR1C3. The synergistic effect of S07-1066 and DOX has been demonstrated in vitro and in vivo, suggesting that AKR1C3 inhibitors may serve as effective adjuvants to overcome AKR1C3-mediated chemotherapy resistance.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease

Xu Tang, Shuaishuai Xing, Mingkang Ma, Ziwei Xu, Qianwen Guan, Yuting Chen, Feng Feng, Wenyuan Liu, Tingkai Chen, Yao Chen, Haopeng Sun

Summary: Parkinson's disease is a neurodegenerative disorder that affects millions of people worldwide. Mutations in the LRRK2 gene are the most common genetic risk factor for PD. Elevated LRRK2 kinase activity is found in both idiopathic and familial PD cases. LRRK2 mutations are involved in various PD pathogeneses, including dysregulation of mitochondrial homeostasis and ciliogenesis.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Design and synthesis of a library of C2-substituted sulfamidoadenosines to probe bacterial permeability

Shibin Zhao, Julian Maceren, Mia Chung, Samantha Stone, Raphael Geiben, Melissa L. Boby, Bradley S. Sherborne, Derek S. Tan

Summary: Antibiotic resistance is a major threat to public health, with Gram-negative bacteria presenting unique challenges due to their low permeability and efflux pumps. Limited understanding of the chemical rules for overcoming these barriers hinders antibacterial drug discovery. Efforts to address this issue, such as screening compound libraries and using cheminformatic analysis, have led to the design of sulfamidoadenosines with diverse substituents, showing potential utility in accumulation in Escherichia coli.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)

Article Chemistry, Medicinal

Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies

Jichun Li, Qing Li, Shuai Xia, Jiahuang Tu, Longbo Zheng, Qian Wang, Shibo Jiang, Chao Wang

Summary: This study successfully developed a short peptide mimetic as a MERS-CoV fusion inhibitor by reproducing the key recognition features of the HR2 helix. The resulting 23-mer lipopeptide showed comparable inhibitory effect to the 36-mer HR2 peptide HR2P-M2. This has important implications for developing short peptide-based antiviral agents to treat MERS-CoV infection.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)

Article Chemistry, Medicinal

Development of novel β2-adrenergic receptor agonists for the stimulation of glucose uptake - The importance of chirality and ring size of cyclic amines

Krista Jaunsleine, Linda Supe, Jana Spura, Sten van Beek, Anna Sandstrom, Jessica Olsen, Carina Halleskog, Tore Bengtsson, Ilga Mutule, Benjamin Pelcman

Summary: Beta(2)-adrenergic receptor agonists can stimulate glucose uptake by skeletal muscle cells and are therefore potential treatments for type 2 diabetes. The chirality of compounds has a significant impact on the activity of these agonists. This study found that certain synthesized compounds showed higher glucose uptake activity. These findings provide important information for the design of novel beta(2)AR agonists for T2D treatment.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)

Article Chemistry, Medicinal

Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)

Xin Xu, Jia Chen, Guan Wang, Xiaojuan Zhang, Qiang Li, Xiaobo Zhou, Fengying Guo, Min Li

Summary: The study focuses on EZH2, a promising therapeutic target for various types of cancers. Researchers designed and synthesized a series of novel derivatives aiming to enhance the EZH2 inhibition activity. Among them, compound 28 displayed potent EZH2 inhibition activity and showed high anti-proliferative effects in lymphoma cell lines and xenograft mouse models. The study suggests that compound 28 has potential as a therapeutic candidate for EZH2-associated cancers.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)

Article Chemistry, Medicinal

The potential of Rhein's aromatic amines for Parkinson's disease prevention and treatment: α-Synuclein aggregation inhibition and disaggregation of preformed fibers

Wei Zhang, Wei Liu, Ya-Dong Zhao, Li-Zi Xing, Ji Xu, Rui-Jun Li, Yun-Xiao Zhang

Summary: This study developed a series of aromatic amide derivatives based on Rhein and investigated their inhibitory activity against alpha-Syn aggregation. Two of these compounds showed promising potential in treating Parkinson's disease by stabilizing alpha-Syn's conformation and disassembling alpha-Syn oligomers and fibrils.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)

Article Chemistry, Medicinal

Design, synthesis and biological evaluation of novel cationic liposomes loaded with melphalan for the treatment of cancer

Mani Sharma, S. S. S. S. Sudha Ambadipudi, Neeraj Kumar Chouhan, V. Lakshma Nayak, Srihari Pabbaraja, Sai Balaji Andugulapati, Ramakrishna Sistla

Summary: Therapeutically active lipids in drug delivery systems can enhance the safety and efficacy of treatment. The liposome formulation created using synthesized biologically active lipids showed additive anti-cancer effects and reduced tumorigenic potential.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2024)